Bristol-Myers Squibb Company vs Merck & Company, Inc. — Stock Comparison
Bristol-Myers Squibb Company (BMY) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Bristol-Myers Squibb Company narrowly edges Merck & Company, Inc. on Q·Score (7 vs 6.3 out of 10), led by Quality (8.8 vs 4.9) and Growth (8.1 vs 6.4). Merck & Company, Inc. scores higher on Sentiment, reflecting stronger analyst and market sentiment. Analyst consensus targets imply greater upside for BMY (-1.2%) than for MRK (-3.1%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 47% return on equity and 19% profit margins.
⚠ analyst sentiment is cautious.
71% of 28 covering analysts have a positive rating.
⚠ weak profitability metrics drag quality score.
Analyst Consensus
Fundamentals
Frequently Asked Questions
BMY vs MRK: which stock scores better overall?
Based on Q·Score, Bristol-Myers Squibb Company (BMY) scores 7/10 versus Merck & Company, Inc. (MRK) at 6.3/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BMY or MRK?
Bristol-Myers Squibb Company (BMY) scores higher on Growth (8.1/10 vs 6.4/10). Bristol-Myers Squibb Company reports revenue growth (5.7% YoY) while Merck & Company, Inc. reports (5.1% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BMY or MRK more attractively valued?
Merck & Company, Inc. (MRK) scores higher on Valuation (6.5/10 vs 5.9/10). BMY trades at 10.2× P/E versus MRK at 16.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BMY vs MRK?
There are 24 analysts covering BMY with a consensus price target of $66.21, and 26 analysts covering MRK with a consensus target of $147.77. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BMY or MRK?
Bristol-Myers Squibb Company (BMY) scores higher on Quality (8.8/10 vs 4.9/10). Net profit margin: BMY at 18.9%, MRK at 4.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BMY or MRK?
Merck & Company, Inc. (MRK) scores higher on Financial Health (7/10 vs 6.1/10). Market beta: BMY at 0.23, MRK at 0.21. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BMY and MRK?
Bristol-Myers Squibb Company (BMY) has a market capitalisation of $136.9B, while Merck & Company, Inc. (MRK) has a market cap of $376.4B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do BMY or MRK pay dividends?
BMY pays a dividend yield of 3.76%, while MRK pays a dividend yield of 2.23%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →